Global scientific partner of choice to accelerate biomedical research

For more than 75 years, Charles River has delivered solutions to accelerate the development of novel drugs and medical devices for the people and patients who need them. We have built upon our original core competency of research model technologies to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, and a suite of products and services to support our clients’ manufacturing activities. Our products and services are provided through three business segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing. With an expansive end-to-end portfolio, global capacity, and proven scientific expertise, our integrated approach allows clients to enhance their productivity and effectiveness at every point along the drug discovery and development continuum, while lowering costs and increasing speed to market.

At Charles River, we are passionate about our role in transforming the drug development process and delivering innovative, safe, and effective treatments to patients, faster. We are proud to have worked on more than 80% of the FDA drug approvals over the last three years. Our mission, our excellent science, and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.